This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Neoplasm of uncertain or unknown behaviour of male genital organs남성생식기관의 행동양식 불명 또는 미상의 신생물

Contents and key points
ItemDetails
A. Classification codesICD-10: D40 (Neoplasm of uncertain or unknown behavior of male genital organs) | Special Copayment Reduction: V193 (Special Copayment Reduction for cancer: copayment 5% for 5 years from the registration date)
B. SynonymsProstate tumor of uncertain behavior (D40.0), testicular tumor of uncertain behavior (D40.1), prostatic intraepithelial neoplasia (PIN III), germ cell neoplasia in situ (GCNIS, formerly CIS), penile intraepithelial neoplasia (PeIN)
C. Adult onsetProstatic PIN presents in men from middle age onward, and testicular GCNIS is common in young adults (15~40 years). Often found incidentally due to elevated PSA or on testicular ultrasound.
1. HistoryThe concept of prostatic PIN was established by McNeal and Bostwick in 1987, and testicular CIS was first reported by Skakkebaek in 1972.
2. CausesAndrogen exposure, age, family history, cryptorchidism, environmental endocrine disruptors, and abnormal germ cell development are the main risk factors.
3. GeneticsBRCA2, AR, FOXA1, and SPOP mutations (prostate); KIT, RAS, and chromosome 12 isochromosome (isochromosome 12p) abnormalities (testis) are the key genetic abnormalities.
4. General epidemiologyHigh-grade PIN is found in about 4~8% of prostate biopsies; testicular GCNIS occurs in about 5~8% of patients with cryptorchidism.
5. PathophysiologyIn prostatic PIN, loss of basal cells and abnormalities of the PTEN/RB pathways drive stepwise malignant transformation; GCNIS results from arrested differentiation of fetal germ cells.
6. SymptomsMostly asymptomatic; high-grade PIN may be accompanied by lower urinary tract symptoms, and GCNIS is found as a testicular mass or cause of infertility.
7. SignsA prostatic nodule on digital rectal examination (DRE), induration or a mass on testicular palpation, and abnormal PSA levels may be found.
8. ScreeningPSA testing and digital rectal examination (prostate), testicular self-examination and ultrasound, and regular urologic checkups for high-risk groups are recommended.
9. DiagnosisProstate biopsy (TRUS or MRI fusion), open testicular biopsy, immunohistochemistry (PLAP, OCT4, CD117), and semen cytology are used.
10. TreatmentClose follow-up for high-grade PIN; radiation therapy or surveillance for GCNIS; prophylactic orchiectomy considered depending on the clinical context.
11. PrognosisProstate cancer develops within 5 years in about 20~30% of patients with high-grade PIN; untreated GCNIS almost always (70% within 7 years) progresses to invasive cancer.
12. PreventionEarly surgical correction of cryptorchidism, chemoprevention (5α-reductase inhibitors), weight management, minimizing exposure to environmental endocrine disruptors.
13. ReferencesProstate intraepithelial neoplasia: significance and correlation with prostate-specific antigen … and 9 other papers

1. History

Among neoplasms of uncertain behavior of the male genital organs, the two most clinically important categories are prostatic intraepithelial neoplasia (PIN) and germ cell neoplasia in situ (GCNIS) of the testis. The history of prostatic PIN begins in 1965 when Andrews described proliferative atypical changes of the prostatic ductal epithelium as "atypical primary epithelial cell hyperplasia". However, the concept of PIN was established in its modern sense in the landmark 1987 study by McNeal and Bostwick. They named precursor lesions showing morphologic continuity with prostatic adenocarcinoma "prostatic intraepithelial neoplasia" and proposed a system classifying them as low grade (LGPIN) and high grade (HGPIN). Numerous studies have since supported HGPIN as a precursor lesion of invasive prostate cancer, and in 1989 the American Society of Pathology formally recognized the clinical importance of HGPIN.

Germ cell neoplasia in situ of the testis was first described in a 1972 report by Niels Skakkebaek of Denmark. Skakkebaek found highly atypical germ cells within the seminiferous tubules of two patients who underwent testicular biopsy for infertility, and later confirmed that invasive testicular cancer developed in both patients. This lesion was long called "intratubular germ cell neoplasia (ITGCN)", "carcinoma in situ (CIS) of the testis", and so on, and the term "germ cell neoplasia in situ (GCNIS)" was formally adopted in the 2016 WHO classification revision. This change reflects that this lesion has biological characteristics different from carcinoma in situ in the traditional sense.

Penile intraepithelial neoplasia (PeIN) has been described since the early 20th century under various names such as Bowen disease and erythroplasia of Queyrat, and was unified as PeIN in the 2004 WHO classification. The dichotomy of HPV-related and HPV-unrelated differentiated types is the current classification standard, and the molecular biological pathways of the two forms have been shown to differ greatly.


2. Causes

The causes of D40 neoplasms are distinguished by site. Risk factors for prostatic high-grade PIN (HGPIN) overlap considerably with those of invasive prostate cancer. Age is the strongest risk factor, and HGPIN increases sharply in men from their 50s onward. With African ancestry, both HGPIN and prostate cancer occur at a younger age and follow a more aggressive course. Family history is also important; when there is a patient with prostate cancer among first- or second-degree relatives, the risk increases 2~3-fold.

Androgens play a key role in the proliferation and survival of prostatic epithelial cells, and dihydrotestosterone (DHT), converted by 5α-reductase, is the main promoting factor. Epidemiologic studies have reported an association between endogenous androgen levels and prostate cancer risk, but individual variation is large. A high-fat diet, obesity, and metabolic syndrome have also been suggested as risk factors, partly related to insulin resistance and activation of the IGF-1 pathway.

The cause of testicular GCNIS is related to abnormal germ cell development in the fetal period. The strongest risk factor is cryptorchidism (GCNIS develops in about 5~8% of patients with cryptorchidism), and in addition hypospadias, a history of contralateral testicular cancer (accompanied by ipsilateral GCNIS in about 2~4%), and Klinefelter syndrome are also risk factors. The "testicular dysgenesis syndrome" hypothesis, which holds that exposure to environmental endocrine disruptors (environmental estrogens, industrial chemicals, DDT metabolites) during the period of germ cell development may increase the risk of GCNIS, is currently attracting attention.

The most important cause of penile PeIN is HPV infection. In HPV-related PeIN (mainly types 16 and 18), the viral proteins E6 and E7 inactivate TP53 and RB, respectively. HPV-unrelated PeIN (differentiated PeIN) is mainly a precursor lesion of squamous cell carcinoma and is associated with chronic skin disease (lichen sclerosus), phimosis, and poor hygiene.


3. Genetics

The major genetic abnormalities observed in prostatic high-grade PIN overlap considerably with those of invasive prostate cancer. PTEN (long arm of chromosome 10) loss is the most common abnormality, observed in about 60~70% of HGPIN. PTEN loss persistently activates the PI3K/AKT signaling pathway, promoting cell survival and proliferation. TMPRSS2-ERG gene fusion is found in over 50% of invasive prostate cancers and is also observed in about 20~25% of HGPIN. This fusion results from fusion of an androgen-responsive gene promoter (TMPRSS2) with an ETS family transcription factor (ERG), and its detection on biopsy is used to distinguish cancer precursor lesions.

Germline BRCA2 mutations are strongly associated with high-grade, high-risk prostate cancer, and the lifetime risk of prostate cancer in BRCA2 mutation carriers increases to about 4~8 times that of the general population. BRCA1 mutations are also associated with increased risk, but the effect is smaller than with BRCA2. Mutations in DNA damage repair genes such as ATM, PALB2, and CHEK2 are also associated with increased prostate cancer risk. An association between prostate cancer risk and the CAG repeat length polymorphism of the androgen receptor (AR) gene (shorter repeats, greater androgen signaling) has also been reported.

The most characteristic genetic abnormality in testicular GCNIS is isochromosome of the short arm of chromosome 12 (isochromosome 12p, i(12p)). This abnormality is observed in almost all invasive testicular germ cell tumors and is also detected in GCNIS, demonstrating genetic continuity between GCNIS and invasive cancer. Activating KIT (CD117) mutations and KRAS mutations are involved in the development of seminoma, and additional chromosomal instability is observed in nonseminomas. Activation of the insulin-like growth factor (IGF) pathway is also identified in GCNIS.


4. General epidemiology

The frequency of detection of prostatic HGPIN increased as PSA-based biopsy became routine. The frequency of a diagnosis of isolated HGPIN (without prostate cancer) on prostate needle biopsy is about 4~8%. By age, it is observed at high frequencies of about 9% in the 40s, 22% in the 50s, 30% in the 60s, and 63% in the 70s, showing a strong association with aging. In African American men, it occurs at a higher frequency and a younger age than in White men.

The prevalence of testicular GCNIS is estimated at about 0.4~1.0% in the general adult male population and is much higher in high-risk groups (cryptorchidism, history of contralateral testicular cancer, Klinefelter syndrome). The frequency of GCNIS in patients with cryptorchidism is reported as about 2~8%. Onset is from puberty onward, when seminiferous tubule changes appear in the mature testis, and the median age of progression to invasive testicular cancer is 20~35 years. High GCNIS incidence is also reported in Northern European countries with a high incidence of testicular cancer (Denmark, Norway, Switzerland).

The epidemiology of penile PeIN differs greatly by geography. Higher incidence is seen in regions with unhygienic environments, phimosis, and high HPV infection rates (South America, Africa, parts of Asia). In East Asia, including Korea, the incidence of penile cancer and PeIN is relatively low. Worldwide, HPV-related PeIN is more frequent in regions with high HPV infection rates.


5. Pathophysiology

Prostatic HGPIN is understood to arise from normal prostatic acinar and ductal epithelium and progress stepwise to invasive prostate cancer. In normal prostatic epithelium, the basal cell layer has a tumor-suppressive function; in HGPIN, this basal cell layer is incompletely preserved and gradually lost, and unregulated proliferation of luminal cells begins. At the molecular level, malignant transformation progresses as telomere shortening and the resulting chromosomal instability, PI3K/AKT pathway activation due to PTEN loss, changes in transcriptional programs due to ERG overexpression, and GSTP1 gene hypermethylation (silencing of a detoxification gene) accumulate stepwise.

Testicular GCNIS is understood as a state in which fetal germ cells (primordial germ cells or gonocytes) fail to differentiate normally and remain in a state of arrested differentiation within the seminiferous tubules. These atypical germ cells retain the gene expression program of fetal germ cells (expression of pluripotency markers such as OCT4, NANOG, and PLAP). After puberty, under gonadotropin and androgen stimulation, these atypical cells proliferate and progress to invasive seminoma or nonseminoma as they acquire additional genetic abnormalities, including i(12p).

In penile HPV-related PeIN, the viral protein E6 degrades p53 via the proteasome pathway, and E7 inactivates Rb, disabling cell cycle checkpoints. As a result, cell cycle progression is activated in an unregulated manner and DNA damage repair is suppressed. In HPV-unrelated differentiated PeIN, TP53 mutation and EGFR overexpression are the key mechanisms.


6. Symptoms

D40 neoplasms are mostly asymptomatic and are found through elevated PSA, testicular abnormalities, or skin lesions. Prostatic HGPIN does not directly cause clinical symptoms and is diagnosed incidentally on biopsy performed because of an abnormal PSA test or abnormal digital rectal examination. However, HGPIN often coexists with benign prostatic hyperplasia, so lower urinary tract symptoms (nocturia, hesitancy, sensation of incomplete emptying) may accompany it, but these are due to prostatic enlargement and are not symptoms of HGPIN itself.

Testicular GCNIS may present as reduced testicular size (atrophy), infertility, or decreased male hormones (low testosterone levels). In some patients, GCNIS is diagnosed during infertility evaluation. When the testis is atrophic or induration is felt, intratubular abnormalities may be identified by ultrasound. Penile PeIN appears on the glans or foreskin as erythematous patches (red lesions, erythroplasia of Queyrat type) or white keratotic lesions (Bowen disease type), and may be accompanied by itching, pain, and discharge. Many cases are asymptomatic and are found on regular gynecologic and urologic checkups.


7. Signs

In prostatic HGPIN, digital rectal examination (DRE) is usually normal, but if the prostate is hard or a nodule is palpable, additional biopsy is needed to exclude invasive cancer. When the PSA level is elevated (especially 4 ng/mL or higher or above age-adjusted thresholds) or the PSA free/total ratio is low, the likelihood of coexisting high-grade PIN or cancer is high. Firmness, asymmetry, and nodules of the prostate influence the decision to biopsy.

In testicular GCNIS, the testis may be reduced in size or palpated with an abnormal (hard) texture. The epididymis may be enlarged, or abnormalities of the spermatic cord may accompany it. In penile PeIN, red velvety lesions on the glans (erythroplasia type), white or brown keratotic patches (Bowen disease type), or multicolored papules and plaques (papulosis bowenoides) are observed. The larger the lesion and the more irregular its margins and the more it is accompanied by ulceration, the greater the likelihood of progression to invasive cancer. Inguinal lymphadenopathy suggests invasive change.


8. Screening

Prostatic HGPIN is not an independent target for screening but is identified in the course of prostate cancer screening. The Korean Urological Association recommends annual PSA testing and DRE in men aged 50 and older, and recommends starting at age 40~45 in men with a family history or of African descent. Prostate biopsy is considered when the PSA level is 4 ng/mL or higher or exceeds the age-specific normal range, or when an abnormality is found on DRE.

For screening for testicular GCNIS, testicular ultrasound and contralateral biopsy are recommended in high-risk groups (cryptorchidism, history of contralateral testicular cancer, Klinefelter syndrome). Contralateral testicular biopsy in patients with testicular cancer is recommended by the European Association of Urology (EAU), and the indication is strengthened especially with reduced testicular size (< 12 mL) or low sperm count. Population screening for testicular GCNIS in men in general is currently not recommended for reasons of cost-effectiveness. For screening for penile PeIN, regular urologic checkups are recommended for men with HPV-related risk factors (multiple sexual partners, uncircumcised, immunocompromised).


9. Diagnosis

The diagnosis of prostatic HGPIN is made by pathologic examination of prostate tissue biopsy specimens. Standard 12-core transrectal ultrasound-guided biopsy (TRUS-guided biopsy) or multiparametric MRI (mpMRI)-guided fusion biopsy is used. When there is a target lesion with a PI-RADS (Prostate Imaging Reporting and Data System) score of 4~5 on mpMRI, fusion biopsy is highly accurate. In pathologic specimens, HGPIN is characterized by clustered proliferation of epithelial cells with atypical nuclei within dilated prostatic ducts, and incomplete preservation of the basal cell layer is observed. On immunohistochemistry, 34βE12 (basal cell marker) and p63 are incompletely positive, and AMACR (α-methylacyl CoA racemase) may be partially positive.

Testicular GCNIS is diagnosed by open testis biopsy, and GCNIS cells appear as large, atypical mononuclear cells arranged along the basement membrane of the seminiferous tubules. On immunohistochemistry, OCT4 (POU5F1), PLAP (placental alkaline phosphatase), NANOG, SOX17, and CD117 (c-Kit) are positively expressed. Among these markers, OCT4 has the highest sensitivity and specificity and is used as the core of diagnosis. Penile PeIN is diagnosed by pathologic examination of biopsy or excision specimens, and the pathology report specifies HPV association, whether it is the differentiated type, and whether the basement membrane is involved. p16 immunohistochemical positivity strongly supports HPV-associated PeIN.


10. Treatment

When HGPIN alone is diagnosed in the prostate, active treatment is not given and close follow-up is the principle. If HGPIN is found on the initial biopsy, repeat biopsy within 1~3 years is needed. Early repeat biopsy is performed especially when the PSA level is rising, a suspicious lesion is present on mpMRI, or there is a family history. 5α-reductase inhibitors (finasteride, dutasteride) have a proven chemopreventive effect against invasive prostate cancer and may be considered in HGPIN patients as well, but they are not routinely recommended.

Treatment of testicular GCNIS is individualized according to the patient's situation (unilateral vs bilateral testicular involvement, contralateral testicular function, pregnancy plans). Low-dose radiation therapy (18~20 Gy) eliminates GCNIS very effectively but damages testicular function (spermatogenesis and hormone secretion). If pregnancy is planned, sperm cryopreservation before treatment is essential. For GCNIS confined to one testis, orchiectomy is the definitive treatment. For bilateral GCNIS, radiation therapy combined with hormone therapy (androgen replacement required) or observation is considered. In penile PeIN, local treatment (5-FU cream, imiquimod, photodynamic therapy, CO2 laser) and excisional surgery are chosen according to lesion size and location.


11. Prognosis

The rate of progression to invasive prostate cancer after a diagnosis of isolated prostatic HGPIN was previously overestimated and subsequently reassessed. In studies before the introduction of mpMRI-guided biopsy, the prostate cancer detection rate on repeat biopsy after HGPIN was reported as 20~30%, but recent studies based on mpMRI-guided biopsy report that the cancer detection rate on repeat biopsy is lower when the first biopsy was performed in the standard manner. Overall, the risk of prostate cancer within 5~10 years after a diagnosis of HGPIN is significantly increased, so regular follow-up is essential.

Untreated, progression of testicular GCNIS to invasive cancer is nearly inevitable. Invasive testicular germ cell tumors are known to develop in about 50% within 5 years and about 70% within 7 years after diagnosis. However, invasive testicular germ cell tumors respond excellently to chemotherapy, so the cure rate is high even when treated after invasive cancer develops, compared with detection and treatment at the GCNIS stage. In this respect, individualization of treatment decisions for GCNIS is important. In penile PeIN, with observation without treatment, invasive penile cancer develops within several years in about 5~10%, and HPV-related PeIN carries a higher risk of invasive transformation than the HPV-unrelated differentiated type.


12. Prevention

The main strategies for preventing prostatic HGPIN and prostate cancer are chemoprevention and lifestyle improvement. 5α-reductase inhibitors (dutasteride, finasteride) were shown in large randomized clinical trials (PCPT, REDUCE) to reduce the incidence of prostate cancer by about 25%. However, because of concern about a relative increase in high-grade prostate cancer (Gleason 8~10), they are applied selectively. Weight management, regular physical activity, and intake of tomatoes (lycopene), green tea, selenium, and so on suggest a preventive effect in observational studies, but the results of large clinical trials are inconsistent.

To prevent testicular GCNIS, early surgical correction of cryptorchidism (orchiopexy) is important. Early surgery before age 2 has been reported to reduce the risk of GCNIS and testicular cancer, but it is not complete prevention. Minimizing exposure to environmental endocrine disruptors, especially reducing maternal exposure during pregnancy, may prevent abnormal germ cell development in the fetal period. To prevent penile PeIN, HPV vaccination (effective in males as well), circumcision of adult men, limiting the number of sexual partners, condom use, and regular skin hygiene are recommended.


13. References

  1. McNeal JE, Bostwick DG. Intraductal dysplasia: a premalignant lesion of the prostate. Hum Pathol. 1986;17(1):64-71. DOI: 10.1016/S0046-8177(86)80152-X. PMID: 3080373.

  2. Skakkebaek NE. Possible carcinoma-in-situ of the testis. Lancet. 1972;2(7776):516-517. DOI: 10.1016/S0140-6736(72)91909-7. PMID: 4115573.

  3. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349(3):215-224. DOI: 10.1056/NEJMoa030660. PMID: 12824459.

  4. Rajpert-De Meyts E, McGlynn KA, Okamoto K, et al. Testicular germ cell tumours. Lancet. 2016;387(10029):1762-1774. DOI: 10.1016/S0140-6736(15)00991-5. PMID: 26651223.

  5. Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2021;79(2):243-262. DOI: 10.1016/j.eururo.2020.09.042. PMID: 33172724.

  6. Aparicio-Siegmund S, Garbers C. Testicular dysgenesis syndrome: an explanation for the increasing incidence of disorders of the male reproductive tract. J Reprod Infertil. 2022;23(3):155-162. PMID: 36405520.

  7. Cheng L, MacLennan GT, Lopez-Beltran A, Montironi R. Histologic grading of urothelial carcinoma: a reappraisal. Hum Pathol. 2012;43(12):2097-2108. DOI: 10.1016/j.humpath.2012.04.015. PMID: 22954551.

  8. Velazquez EF, Chaux A, Cubilla AL. Histologic classification of penile intraepithelial neoplasia. Semin Diagn Pathol. 2012;29(2):96-102. DOI: 10.1053/j.semdp.2012.01.006. PMID: 22641008.

  9. Leão R, Ahmad AE, Hamilton RJ. Testicular germ cell tumor biomarkers: a review. Semin Oncol. 2019;46(1):36-44. DOI: 10.1053/j.seminoncol.2018.12.003. PMID: 30527516.

  10. Verze P, Cai T, Lorenzetti S. The role of the prostate in male fertility, health and disease. Nat Rev Urol. 2016;13(7):379-386. DOI: 10.1038/nrurol.2016.89. PMID: 27245504.